###begin article-title 0
###xml 19 24 <span type="species:ncbi:10090">Mouse</span>
iNKT Cells Control Mouse Spontaneous Carcinoma Independently of Tumor-Specific Cytotoxic T Cells
###end article-title 0
###begin p 1
Conceived and designed the experiments: MB GC. Performed the experiments: MC MG EJ AC AN MF. Analyzed the data: MB MC MG EJ AC AN MF GC PD. Contributed reagents/materials/analysis tools: MF. Wrote the paper: MB GC PD.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 439 444 <span type="species:ncbi:10090">mouse</span>
CD1d-restricted invariant NKT (iNKT) cells are a subset of T lymphocytes endowed with innate effector functions that aid in the establishment of adaptive T and B cell immune responses. iNKT cells have been shown to play a spontaneous protective role against experimental tumors. Yet, the interplay between iNKT and tumor-specific T cells in cancer immune surveillance/editing has never been addressed. The transgenic adenocarcinoma of the mouse prostate (TRAMP) is a realistic model of spontaneous oncogenesis, in which the tumor-specific cytotoxic T cell (CTL) response undergoes full tolerance upon disease progression.
###end p 3
###begin title 4
Principal Findings
###end title 4
###begin p 5
###xml 48 52 <span type="species:ncbi:10090">mice</span>
###xml 171 175 <span type="species:ncbi:10090">mice</span>
We report here that lack of iNKT cells in TRAMP mice resulted in the appearance of more precocious and aggressive tumors that significantly reduced animal survival. TRAMP mice bearing or lacking iNKT cells responded similarly to a tumor-specific vaccination and developed tolerance to a tumor-associated antigen at comparable rate.
###end p 5
###begin title 6
Conclusions
###end title 6
###begin p 7
Hence, our data argue for a critical role of iNKT cells in the immune surveillance of carcinoma that is independent of tumor-specific CTL.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 154 157 154 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Dunn1">[1]</xref>
###xml 266 269 266 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Smyth1">[2]</xref>
###xml 513 516 513 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Dougan1">[3]</xref>
Several lines of evidence in pre-clinical and clinical studies support the notion that tumor cell growth is under the active control of the immune system [1]. Cancer immune surveillance is the result of concerted actions between innate and adaptive immune responses [2]. T cell responses specific for tumor-associated antigens (TAA) presented by MHC molecules on cancer cells play a central role in cancer immune surveillance, and can be increased by different immunotherapy strategies in attempts to cure cancer [3].
###end p 9
###begin p 10
###xml 92 95 92 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Bendelac1">[4]</xref>
###xml 253 256 237 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Lantz1">[5]</xref>
###xml 258 261 242 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Dellabona1">[6]</xref>
###xml 420 423 388 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Bendelac1">[4]</xref>
###xml 552 555 520 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Brigl1">[7]</xref>
###xml 223 227 <span type="species:ncbi:10090">mice</span>
###xml 232 238 <span type="species:ncbi:9606">humans</span>
###xml 393 397 <span type="species:ncbi:10090">mice</span>
###xml 413 419 <span type="species:ncbi:9606">humans</span>
iNKT cells are a subset of conserved T lymphocytes that bridge innate and adaptive immunity [4]. They are characterized by the expression of the homologous invariant (i)Valpha14-Jalpha18 and Valpha24-Jalpha18 TCR chains in mice and humans, respectively [5], [6]. The iValpha chains pair with a set of variable TCRbeta chains exhibiting a very restricted Vbeta gene usage: Vbeta8.2, 7 and 2 in mice and Vbeta11 in humans [4]. This semi-invariant TCR recognizes endogenous or exogenous lipid antigens (Ag) presented by the MHC-class I like molecule CD1d [7].
###end p 10
###begin p 11
###xml 184 187 184 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Godfrey1">[8]</xref>
###xml 406 409 398 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Kronenberg1">[9]</xref>
###xml 506 509 498 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Kronenberg1">[9]</xref>
###xml 674 675 666 667 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 683 684 675 676 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 749 753 741 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Fujii1">[10]</xref>
###xml 755 759 747 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Tonti1">[11]</xref>
###xml 935 939 927 931 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Nagarajan1">[12]</xref>
###xml 204 208 <span type="species:ncbi:10090">mice</span>
Unlike MHC-restricted T cells, iNKT cells exhibit an effector-memory phenotype independently of foreign Ag encounter, acquired in the thymus following a distinct developmental pathway [8]. Injection into mice of the CD1d-restricted glycosphingolipid Ag alphaGalactosylCeramide (alphaGalCer) potently activates iNKT cells, triggering within hours copious production of a wide range of Th1 and Th2 cytokines [9]. These cytokines, in turn, activate effector cells of both innate and adaptive immune responses [9]. iNKT cell interaction with CD1d-expressing immature dendritic cells (DC) results in the licensing of antigen presenting functions, which facilitates priming of CD4+ and CD8+ T cell and B cell responses specific for concomitant protein Ag [10], [11]. Furthermore, cytokine production by iNKT cells can be triggered independently of TCR engagement, for instance by the action of inflammatory cytokines such as IL-12 and IL-18 [12].
###end p 11
###begin p 12
###xml 197 201 197 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Cerundolo1">[13]</xref>
###xml 203 207 203 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Terabe1">[14]</xref>
###xml 506 510 502 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Tahir1">[15]</xref>
###xml 512 516 508 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Dhodapkar1">[16]</xref>
###xml 518 522 514 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Tachibana1">[17]</xref>
###xml 524 528 520 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Molling1">[18]</xref>
###xml 296 301 <span type="species:ncbi:9606">human</span>
Because of these peculiar innate-like effector characteristics, iNKT cells are regarded as potent adjuvant involved in the early activation of the immune response and in cancer immune surveillance [13], [14]. Consistent with this function, circulating iNKT cell number have been found reduced in human solid tumors, while IFN-gamma production and number of iNKT cells appear to correlate with a more favorable prognosis in multiple myeloma, colorectal cancer, head and neck cancer and prostate cancer (PC) [15], [16], [17], [18].
###end p 12
###begin p 13
###xml 36 43 32 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 194 198 190 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Taniguchi1">[19]</xref>
###xml 200 204 196 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Swann1">[20]</xref>
###xml 206 210 202 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Hayakawa1">[21]</xref>
iNKT cell activation by alphaGalCer in vivo results in the subsequent activation of NK and T cells, leading to the growth control of both transplantable tumors and spontaneous mammary carcinoma [19], [20], [21].
###end p 13
###begin p 14
###xml 233 236 225 228 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 323 327 315 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Crowe1">[22]</xref>
###xml 508 509 496 497 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 521 525 509 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Crowe2">[23]</xref>
###xml 681 685 669 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Swann2">[24]</xref>
###xml 799 802 787 790 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 183 187 <span type="species:ncbi:10090">Mice</span>
###xml 237 241 <span type="species:ncbi:10090">mice</span>
###xml 636 640 <span type="species:ncbi:10090">mice</span>
###xml 803 807 <span type="species:ncbi:10090">mice</span>
iNKT cells display also a spontaneous anti-tumor function, which occurs independently of alphaGalCer administration, possibly induced by the recognition of endogenous lipid antigens. Mice selectively deficient in iNKT cells (Jalpha18-/- mice) are in fact significantly more susceptible to chemically induced carcinogenesis [22]. In this model, adoptive cell transfer experiments established that the protection from methylcholanthrene (MCA)-induced fibrosarcoma is mediated by IFN-gamma-producing hepatic CD4- iNKT cells [23]. Furthermore, iNKT cells spontaneously suppress the growth of osteosarcoma and hematopoietic tumors caused in mice by the loss of the tumor suppressor p53 [24]. Because of the lack of a traceable tumor Ag-specific T cell response in both MCA-induced tumor models and in p53+/- mice, and development of different and unpredictable tumor types in the latter, it is difficult to correlate the presence or lack of iNKT with tumor-specific a CTL response and its involvement in cancer immune surveillance.
###end p 14
###begin p 15
###xml 243 247 243 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Greenberg1">[25]</xref>
###xml 548 552 548 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Shappel1">[26]</xref>
###xml 691 695 691 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Zheng1">[27]</xref>
###xml 842 849 842 849 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">404&#8211;411</sub>
###xml 859 863 859 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Mylin1">[28]</xref>
###xml 973 977 973 977 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-DeglInnocenti1">[29]</xref>
###xml 1019 1023 1019 1023 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-DeglInnocenti1">[29]</xref>
###xml 1025 1029 1025 1029 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-DeglInnocenti2">[30]</xref>
###xml 1104 1108 1104 1108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Drake1">[31]</xref>
###xml 1147 1151 1147 1151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Savage1">[32]</xref>
###xml 1234 1238 1234 1238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Miller1">[33]</xref>
###xml 33 38 <span type="species:ncbi:10090">mouse</span>
###xml 56 60 <span type="species:ncbi:10090">mice</span>
###xml 73 77 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 152 155 <span type="species:ncbi:10116">rat</span>
###xml 261 265 <span type="species:ncbi:10090">mice</span>
###xml 326 330 <span type="species:ncbi:10090">mice</span>
###xml 383 388 <span type="species:ncbi:10090">mouse</span>
###xml 539 544 <span type="species:ncbi:9606">human</span>
###xml 563 567 <span type="species:ncbi:10090">mice</span>
###xml 769 773 <span type="species:ncbi:10090">mice</span>
###xml 1079 1083 <span type="species:ncbi:10090">mice</span>
###xml 1200 1208 <span type="species:ncbi:9606">patients</span>
Transgenic adenocarcinoma of the mouse prostate (TRAMP) mice express the SV40 large T antigen (Tag) in the prostate epithelium under the control of the rat probasin regulatory element. Sexual hormones influence the expression of the transgene [25]; hence, male mice remain healthy until puberty. In the following weeks, TRAMP mice over-express Tag and invariably develop spontaneous mouse prostate intraepithelial neoplasia (mPIN), which progress to adenocarcinoma and seminal vesicles, lymph node (LN) and visceral metastases, resembling human PC [26]. In TRAMP mice, the immune response against the surrogate tissue-specific TAA Tag is characterized by thymic deletion of high avidity CTL [27]. As a consequence, vaccination with Tag-pulsed DC in young healthy TRAMP mice elicits low avidity CTL specific for the immunodominant sequence Tag404-411 (Tag-IV) [28]. In parallel with PC development and progression, these CTL undergo a profound state of peripheral tolerance [29] that cannot be rescued by DC vaccination [29], [30]. A similar phenomenon has been reported in TRAMP mice for other surrogate [31] and natural tumor associated antigens [32], and recapitulates the tolerant status found in patients with advanced PC disease [33].
###end p 15
###begin p 16
Given the data on anti-tumor roles of NKT cells in transplantable and carcinogen tumor models together with the clinical relevance of the TRAMP model, we investigated whether iNKT cells control the growth of spontaneous PC, and whether this phenomenon depends on the interplay between iNKT and tumor-specific T cells.
###end p 16
###begin title 17
Materials and Methods
###end title 17
###begin title 18
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice, Tumor Cell Lines and Reagents
###end title 18
###begin p 19
###xml 189 193 189 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Greenberg1">[25]</xref>
###xml 335 338 327 330 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 451 454 439 442 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 529 532 513 516 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1008 1009 992 993 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 1041 1045 1025 1029 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Ljunggren1">[34]</xref>
###xml 1092 1096 1076 1080 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Tanaka1">[35]</xref>
###xml 1155 1159 1139 1143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Foster1">[36]</xref>
###xml 19 23 <span type="species:ncbi:10090">mice</span>
###xml 302 306 <span type="species:ncbi:10090">mice</span>
###xml 455 459 <span type="species:ncbi:10090">mice</span>
###xml 533 537 <span type="species:ncbi:10090">mice</span>
###xml 631 635 <span type="species:ncbi:10090">mice</span>
###xml 1149 1154 <span type="species:ncbi:10090">mouse</span>
Heterozygous TRAMP mice on a C57BL/6 background were obtained from Dr. A Vitiello (The R.W. Johnson Pharmaceutical Research Institute, San Diego, CA), originated from the founder male 8247 [25], and were bred by crossing heterozygous TRAMP females with wild type (WT) C57BL/6 males. B6.129-Tcra-Jtm1tg mice Jalpha18-deficient (Jalpha18-/-) were obtained from Dr. M. Taniguchi (RIKEN, Yokohama, Japan) and backcrossed 12 times to C57BL/6. TRAMPJalpha18-/- mice were generated at San Raffaele by crossing TRAMP and C57BL/6 Jalpha18-/- mice. Animals were typed for Tag expression by PCR-based screening assay, as described in (). All mice were housed and bred in a specific pathogen free animal facility. All procedures involving animals were reviewed and approved by the Institutional Animal Care and Use Committee at San Raffaele Scientific Institute. Animals were monitored twice a week for weight and tumor growth, and euthanized when signs of bulky prostate tumor and/or distress were evident. RMA is a H-2b Rauscher virus-induced thymoma [34]. B6/K-0 is a kidney cell line, expressing Tag [35]. TRAMP-C1 is a PC cell line originated from a TRAMP mouse [36]. Unless specified, all chemical reagents were from Sigma-Aldrich, and mAb were from BD PharMingen (San Diego, CA).
###end p 19
###begin title 20
DC Preparation and Immunization Protocols
###end title 20
###begin p 21
###xml 59 63 59 63 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Camporeale1">[37]</xref>
###xml 149 156 141 148 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">181&#8211;200</sub>
###xml 252 253 238 239 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 272 273 258 259 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 462 463 444 445 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 476 480 458 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Iezzi1">[38]</xref>
###xml 562 563 544 545 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 575 576 557 558 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 708 712 690 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-DeglInnocenti1">[29]</xref>
###xml 1282 1286 1241 1245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Fedeli1">[39]</xref>
###xml 301 305 <span type="species:ncbi:10090">mice</span>
###xml 486 490 <span type="species:ncbi:10090">mice</span>
###xml 775 780 <span type="species:ncbi:10090">mouse</span>
DC were prepared and characterized as previously described [37]. DC were pulsed with 2 microM Tag-IV or 1 microM tyrosinase related protein 2 peptide181-200 (TRP-2; Research Genetics, Huntsville, AL) for 1 h at 37degreesC, washed, and suspended at 1x106/ml in PBS. Fivex105 DC were injected i.d. into mice. When requested, alphaGalCer (100 ng/ml) was added to the DC cultures 3 h before cell recovery. Magnetic-bead (Miltenyi Biotec, Bologna, Italy) enriched CD8+ splenocytes [38] from mice euthanized one week after DC vaccination were stained with PE-labeled Kb/Tag-IV or Kb/OVA (SIINFEKL) pentamers (ProImmune, Oxford, UK), CD8, CD44, and dump (B220, CD11c, CD19, CD4) mAbs and analyzed by flow cytometry [29]. For functional analysis of iNKT cells, alphaGalCer (2 microg/mouse; Alexis, Lausen, Switzerland) was administered i.v. Blood samples were collected from the tail vein 2, 6 and 24 hours later, and the serum content of IL-4 and IFN-gamma was determined by standard ELISA (BD Pharmingen, San Diego, CA). Animals were euthanized 72 hours after alphaGalCer treatment, and the number of iNKT cells in their spleen and liver was determined by staining with alphaGalCer-mCD1d tetramers (provided by the NIH Tetramer Facility) and anti-TCRbeta mAbs and flow cytometry analysis [39].
###end p 21
###begin title 22
In Vitro Cytotoxicity Assay
###end title 22
###begin p 23
###xml 31 39 31 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 159 161 155 157 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">51</sup>
###xml 178 182 174 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Camporeale1">[37]</xref>
###xml 184 186 180 182 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">51</sup>
###xml 246 248 242 244 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">51</sup>
Splenocytes were re-stimulated in vitro in the presence of 1 microM Tag IV or TRP-2 peptide. Day-5-blasts were tested for cytolytic activity in a standard 4 h 51Cr release assay [37]. 51Cr release of target cells alone was always <25% of maximal 51Cr release (target cells in 0.25 M SDS).
###end p 23
###begin title 24
Histology and Immunohistochemistry
###end title 24
###begin p 25
###xml 211 215 211 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-DeglInnocenti2">[30]</xref>
###xml 362 366 362 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-DeglInnocenti2">[30]</xref>
###xml 368 372 368 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Bertilaccio1">[40]</xref>
###xml 444 445 444 445 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 515 516 513 514 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1109 1110 1107 1108 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
The urogenital apparatus (UGA) was excised, weighted, fixed in 4% formalin for 6 h, then embedded and included in paraffin wax. H&E and Tag staining of 5-mm thick sections were performed as previously described [30]. Macroscopic and microscopic specimens were evaluated by a pathologist in a blind fashion. Histology sections were scored as previously described [30], [40] with partial modifications: 0, healthy tissue; <1, scattered (<20%) Tag+ cells with mild increase of nucleus to cytoplasm ratio; 1, >/=20% Tag+ cells with increasing nucleus to cytoplasm ratio, nuclear hyperchromasia, stratification and micro-papillary projections; 2, presence of all the features described in 1 and cribriform structures with mild enlargement of acini; 3, presence of all the features described in 2 and either proliferation of the epithelial and stromal cells of the seminal vesicles or mild proliferation of smooth muscle stromal cells of prostatic acini with acinar enlargement; 4, presence of all the features described in 3 and marked proliferation of smooth muscle stromal cells with penetration of malignant Tag+ cells through the basement membrane of mPIN-involved glands into the surrounding stroma; 5, well differentiated adenocarcinoma; and 6, presence of metastasis and/or neuroendocrine tumors.
###end p 25
###begin title 26
Statistical Analysis
###end title 26
###begin p 27
###xml 54 55 54 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
Statistical analyses were performed using the Student t-test, the Log-Rank and the Mann-Whitney tests. Comparison of survival curves was considered statistically significant for p<0.05.
###end p 27
###begin title 28
Results
###end title 28
###begin title 29
###xml 18 22 <span type="species:ncbi:10090">Mice</span>
Survival of TRAMP Mice Lacking iNKT Cells Is Reduced
###end title 29
###begin p 30
###xml 128 131 124 127 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 445 451 439 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008646-g001">Fig. 1</xref>
###xml 466 469 456 459 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 132 136 <span type="species:ncbi:10090">mice</span>
###xml 189 193 <span type="species:ncbi:10090">mice</span>
###xml 470 474 <span type="species:ncbi:10090">mice</span>
###xml 730 734 <span type="species:ncbi:10090">mice</span>
###xml 794 798 <span type="species:ncbi:10090">mice</span>
To investigate the role of iNKT cells in immune surveillance against a spontaneous solid cancer, we generated male TRAMPJalpha18-/- mice, and compared their survival with a cohort of TRAMP mice. Animals were euthanized when signs of bulky prostate tumor and/or distress were manifest. Anatomy and histology of the UGA confirmed the presence of aggressive prostate tumors in all animals (i.e., disease score >/=4; data not shown). As reported in Fig. 1, TRAMPJalpha18-/- mice exhibited a reduced disease-free survival, and all animals in this cohort were euthanized before week 38. At this time, approximately 60% of the TRAMP animals were still alive and apparently tumor free. Comparison of survival curves of the two cohorts of mice revealed a highly significant prolonged survival for TRAMP mice (p<0.0001). Hence, the lack of iNKT cells appears to greatly affect tumorigenesis in this model.
###end p 30
###begin title 31
###xml 18 22 <span type="species:ncbi:10090">mice</span>
Survival of TRAMP mice lacking iNKT cells is reduced.
###end title 31
###begin p 32
###xml 113 116 109 112 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 346 366 342 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s2">Material and Methods</xref>
###xml 117 121 <span type="species:ncbi:10090">mice</span>
Kaplan-Maier plot reporting the survival curves of groups of male TRAMP (black squares; n = 21) and TRAMPJalpha18-/- mice (black circles; n = 21). Animals were examined twice a week and euthanized when signs of bulky prostate tumor and/or distress were manifest. At necropsy, the anatomy and histology of the UGA was analyzed as indicated in the Material and Methods section. Animals were attributed a disease score>/=4. Statistical comparison (Log-Rank test) between the survival curves: p<0.0001.
###end p 32
###begin title 33
###xml 36 40 <span type="species:ncbi:10090">Mice</span>
Tumor Onset Is Accelerated in TRAMP Mice Lacking iNKT Cells
###end title 33
###begin p 34
###xml 94 97 90 93 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 138 141 130 133 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 451 455 443 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Chiaverotti1">[41]</xref>
###xml 498 501 486 489 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 783 786 767 770 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 918 925 902 909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008646-g002">Fig. 2A</xref>
###xml 1032 1035 1012 1015 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1184 1191 1164 1171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008646-g002">Fig. 2A</xref>
###xml 98 102 <span type="species:ncbi:10090">mice</span>
###xml 142 146 <span type="species:ncbi:10090">mice</span>
###xml 502 506 <span type="species:ncbi:10090">mice</span>
###xml 832 836 <span type="species:ncbi:10090">mice</span>
###xml 1052 1056 <span type="species:ncbi:10090">mice</span>
To better define the time of appearance and aggressiveness of prostate tumors in TRAMPJalpha18-/- mice, cohorts of TRAMP and TRAMPJalpha18-/- mice were sacrificed at different weeks after birth and full autopsy was performed. Animals with bulky and round-shaped prostate masses, which were histologically confirmed to be neuroendocrine prostate tumors, were excluded from the study because appearance of these lesions is stochastic in the TRAMP model [41]. Macroscopically, the UGA of TRAMPJalpha18-/- mice appeared larger than that of age-matched WT and even TRAMP males, with seminal vesicles particularly engorged already at 17-18 weeks of age (data not shown). Indeed, the UGA weight, an accepted parameter to measure disease progression in this model, of TRAMP and TRAMPJalpha18-/- males was higher than that of age-matched WT mice at weeks 17-24, and the difference further increased during the following weeks (Fig. 2A; p<0.0001). Furthermore, a highly statistically significant difference in UGA weight between TRAMPJalpha18-/- and WT or TRAMP mice was present already at 12-16 weeks (p<0.0001), time at which there was no difference in UGA weight between TRAMP and WT males (Fig. 2A).
###end p 34
###begin title 35
###xml 36 40 <span type="species:ncbi:10090">mice</span>
Tumor onset is accelerated in TRAMP mice lacking iNKT cells.
###end title 35
###begin p 36
###xml 67 70 63 66 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 244 264 240 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s2">Material and Methods</xref>
###xml 401 404 391 394 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 837 838 825 826 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 99 103 <span type="species:ncbi:10090">mice</span>
###xml 412 416 <span type="species:ncbi:10090">mice</span>
Age- and sex-matched male TRAMP (white bars; n = 97), TRAMPJalpha18-/- (black bars; n = 51) and WT mice (gray bars; n = 97) were killed at the indicated week after birth and the anatomy and histology of the UGA was analyzed as indicated in the Material and Methods section. Animals affected by neuroendocrine tumors were excluded. A, UGA weight (g), expressed as average+/-SEM, of TRAMP, TRAMPJalpha18-/- and WT mice killed at weeks 6-8 (n = 5, 8 and 19, respectively), 12-16 (n = 16, 17 and 26), 17-24 (n = 30, 15 and 26) and 25-28 (n = 46, 11 and 26), respectively. B, ratio of the weight of UGA and body weight subtracted of the UGA in the groups of animals reported above. C, Disease score, expressed as average+/-SEM, of the groups of animals reported above. Statistical analysis of collected data was performed using the Student's t-test (A and B) and the Mann-Whitney test (C); ***p<0.001, **0.001<p<0.05, *0.01<p<0.05.
###end p 36
###begin p 37
###xml 140 143 136 139 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 289 296 285 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008646-g002">Fig. 2A</xref>
###xml 331 338 327 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008646-g002">Fig. 2B</xref>
###xml 144 148 <span type="species:ncbi:10090">mice</span>
Difference in UGA weight was likely due to more advanced/aggressive tumors and not to a generalized increase in body weight of TRAMPJalpha18-/- mice. Indeed, when the ratio of the weight of UGA and body weight subtracted of the UGA was calculated for all groups of animals reported above (Fig. 2A), differences were all confirmed (Fig. 2B).
###end p 37
###begin p 38
###xml 126 129 122 125 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 480 483 472 475 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 587 591 579 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-DeglInnocenti2">[30]</xref>
###xml 612 619 604 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008646-g002">Fig. 2C</xref>
###xml 670 673 658 661 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 807 810 791 794 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 854 861 838 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008646-g002">Fig. 2C</xref>
###xml 130 134 <span type="species:ncbi:10090">mice</span>
###xml 458 462 <span type="species:ncbi:10090">mice</span>
###xml 484 488 <span type="species:ncbi:10090">mice</span>
###xml 674 678 <span type="species:ncbi:10090">mice</span>
Prostate tissues were also investigated microscopically. No difference in disease score was present in TRAMP and TRAMPJalpha18-/- mice at 6-8 weeks of age, and most of the prostates at H&E staining showed scattered foci of cells with nuclear elongation, altered nucleus-to-cytoplasm ratio and micro-papillary projections, sometimes accompanied by cribriform structures and mild enlargement of acini (data not shown). Expression of Tag in 6-8 weeks old TRAMP mice and TRAMPJalpha18-/- mice had a dim and patchy distribution overlapping pathologic foci (data not shown), with, as expected [30], a disease score<2 (Fig. 2C). In the following weeks, lesions in TRAMPJalpha18-/- mice appeared more aggressive than that of age-matched TRAMP animals, and the disease score was significantly higher in TRAMPJalpha18-/- than in TRAMP animals at all weeks tested (Fig. 2C).
###end p 38
###begin p 39
###xml 101 104 97 100 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 356 359 348 351 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 105 109 <span type="species:ncbi:10090">mice</span>
###xml 152 156 <span type="species:ncbi:10090">mice</span>
###xml 261 265 <span type="species:ncbi:10090">mice</span>
###xml 360 364 <span type="species:ncbi:10090">mice</span>
###xml 396 400 <span type="species:ncbi:10090">mice</span>
Interestingly, invasive adenocarcinoma (disease score 5) was found in 4 out of 13 (31%) TRAMPJalpha18-/- mice and in zero out of 8 18-19 week old TRAMP mice. In the TRAMP colony indeed, the earliest invasive adenocarcinoma was found at week 23. When cohorts of mice were sacrificed at week 25-28, adenocarcinoma was found in 7 out of 11 (64%) TRAMPJalpha18-/- mice versus 7 out of 46 (15%) TRAMP mice.
###end p 39
###begin p 40
###xml 89 93 89 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Crowe1">[22]</xref>
###xml 106 110 106 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Swann2">[24]</xref>
###xml 140 144 <span type="species:ncbi:10090">mice</span>
Hence, spontaneous PC development and progression, as reported for tumors induced by MCA [22] or p53 loss [24], is more aggressive in TRAMP mice lacking iNKT cells.
###end p 40
###begin title 41
###xml 73 76 69 72 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 77 81 <span type="species:ncbi:10090">Mice</span>
Similar Behavior of Tag-Specific CTL Responses in TRAMP and TRAMPJalpha18-/- Mice
###end title 41
###begin p 42
###xml 252 259 252 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 335 338 331 334 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 344 348 340 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-DeglInnocenti2">[30]</xref>
###xml 373 380 369 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 439 446 435 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 809 813 805 809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-DeglInnocenti1">[29]</xref>
###xml 815 819 811 815 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-DeglInnocenti2">[30]</xref>
###xml 226 230 <span type="species:ncbi:10090">mice</span>
###xml 339 343 <span type="species:ncbi:10090">mice</span>
###xml 494 498 <span type="species:ncbi:10090">mice</span>
###xml 538 542 <span type="species:ncbi:10090">mice</span>
We next sought to investigate whether the iNKT cell-dependent anti-tumor functions could be related to the induction and maintenance of a spontaneous TAA-specific CTL response. The low frequency of tumor-specific CTL in TRAMP mice precluded the direct ex vivo comparison of frequency, phenotype and functions in TRAMP and TRAMPJalpha18-/- mice [30]. However, the detection ex vivo of tumor-specific CTL responses can be achieved following in vivo expansion, obtained upon immunization of TRAMP mice with specific TAA. By immunizing TRAMP mice with DC pulsed with the TAA Tag, we were in fact able to detect a specific CTL response. Furthermore, we previously showed that PC growth is accompanied by the progressive induction of a Tag-specific CTL tolerance that reaches a full state at around 11 weeks of age [29], [30].
###end p 42
###begin p 43
###xml 81 84 77 80 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 204 207 196 199 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 357 364 349 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ex vivo</italic>
###xml 425 426 417 418 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 430 431 422 423 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 432 433 424 425 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 439 440 431 432 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 498 501 486 489 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 582 589 566 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 650 653 630 633 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 178 182 <span type="species:ncbi:10090">mice</span>
###xml 215 219 <span type="species:ncbi:10090">mice</span>
###xml 502 506 <span type="species:ncbi:10090">mice</span>
###xml 654 658 <span type="species:ncbi:10090">mice</span>
To determine whether the precocious and more aggressive PC found in TRAMPJalpha18-/- was due to the establishment of Tag-specific CTL tolerance at an earlier stage than in TRAMP mice, TRAMP, TRAMPJalpha18-/- and WT mice were immunized once i.d. with Tag-IV pulsed DC at week 6-8, when tumor-specific CTL are still functional, and sacrificed one week later. Ex vivo flow-cytometry analysis showed a comparable frequency of CD8+CD44+Kb/TagIV+ cells in the spleen of vaccinated TRAMP and TRAMPJalpha18-/- mice (0.9+/-0.14 and 1.31+/-0.5%, respectively), therefore indicating a similar in vivo expansion of Tag-specific T cells in TRAMP and TRAMPJalpha18-/- mice.
###end p 43
###begin p 44
###xml 81 84 77 80 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 188 201 184 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008646-g003">Fig. 3A and B</xref>
###xml 239 243 235 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-DeglInnocenti2">[30]</xref>
###xml 293 300 289 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008646-g003">Fig. 3C</xref>
###xml 341 342 337 338 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 359 365 355 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008646-g003">Fig. 3</xref>
###xml 521 524 513 516 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 627 631 619 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-DeglInnocenti2">[30]</xref>
###xml 725 731 717 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008646-g003">Fig. 3</xref>
###xml 287 291 <span type="species:ncbi:10090">mice</span>
###xml 471 475 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 852 856 <span type="species:ncbi:10090">mice</span>
Upon in vitro Ag-specific restimulation, splenocytes from TRAMP and TRAMPJalpha18-/- demonstrated a comparable, consistent and specific cytolytic activity against Tag-IV-pulsed RMA cells (Fig. 3A and B, respectively) that was, as expected [30], lower than the one found in WT vaccinated mice (Fig. 3C). CTL blasts efficiently killed also Tag+ B6/K-0 targets (Fig. 3), therefore demonstrating that these CTL were able to recognize the endogenously processed and presented SV40 epitope. When cohorts of TRAMP, TRAMPJalpha18-/- and WT males were immunized after week 10, at which point, tumor-specific CTL tolerance is full-blown [30], a Tag-specific immune response was detected only in splenocytes from vaccinated WT animals (Fig. 3, panels D, E and F, respectively), suggesting that tolerance of Tag-specific CTL proceeded at comparable rates in TRAMP mice bearing or lacking iNKT cells.
###end p 44
###begin title 45
###xml 72 75 68 71 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 76 80 <span type="species:ncbi:10090">mice</span>
The immune response against Tag is comparable in TRAMP and TRAMPJalpha18-/- mice.
###end title 45
###begin p 46
###xml 119 122 115 118 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 256 264 252 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 355 357 351 353 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">51</sup>
Tag-IV-pulsed DC were injected once i.d. into 6- (panels A-C) and 16-week (D-F) old male TRAMP (A and D), TRAMPJalpha18-/- (B and E) and WT age- and sex-matched littermates (C and F). After 7 days, animals were killed and their splenocytes were stimulated in vitro with irradiated B6/K-0 cells, and tested 5 days later for cytotoxic activity (measured as 51Cr release); un-pulsed (black squares) or Tag-IV-pulsed (black diamonds) RMA and B6/K-0 (black circles) cells were used as targets. Data correspond to one out of at least three independent experiments, which gave similar results.
###end p 46
###begin p 47
###xml 90 93 86 89 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 202 205 194 197 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 272 273 264 265 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 324 330 316 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008646-g004">Fig. 4</xref>
###xml 465 468 453 456 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 94 98 <span type="species:ncbi:10090">mice</span>
###xml 213 217 <span type="species:ncbi:10090">mice</span>
###xml 346 350 <span type="species:ncbi:10090">mice</span>
###xml 469 473 <span type="species:ncbi:10090">mice</span>
To investigate whether lack of immune response against Tag in aged TRAMP and TRAMPJalpha18-/- mice reflected a generalized immune suppression or was specific for the TAA, cohorts of TRAMP, TRAMPJalpha18-/- and WT mice were immunized with DC pulsed with the unrelated and Kb-restricted melanoma antigen TRP-2. As reported in Fig. 4, all groups of mice generated a comparable TRP-2-specific CTL response, therefore confirming that tolerance in TRAMP and TRAMPJalpha18-/- mice is restricted to the PC-associated antigen.
###end p 47
###begin title 48
###xml 27 31 <span type="species:ncbi:10090">mice</span>
Tolerance in tumor-bearing mice is specific for the PC-related Ag Tag.
###end title 48
###begin p 49
###xml 95 98 91 94 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 241 249 237 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 334 336 330 332 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">51</sup>
TRP-2-pulsed DC were injected once i.d. into 16-week old male TRAMP (left panel), TRAMPJalpha18-/- (middle panel) and WT age- and sex-matched littermates (right panel). After 7 days, animals were killed and their splenocytes were stimulated in vitro with the TRP-2 peptide, and tested 5 days later for cytotoxic activity (measured as 51Cr release); un-pulsed (black diamonds) or TRP-2-pulsed (black triangles) RMA cells were used as targets. Each panel is representative of at least two independent experiments.
###end p 49
###begin p 50
###xml 245 249 241 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Fujii1">[10]</xref>
###xml 685 691 661 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008646-g005">Fig. 5</xref>
###xml 1186 1194 1154 1162 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 48 52 <span type="species:ncbi:10090">mice</span>
###xml 357 361 <span type="species:ncbi:10090">mice</span>
###xml 476 480 <span type="species:ncbi:10090">mice</span>
###xml 769 773 <span type="species:ncbi:10090">mice</span>
###xml 956 960 <span type="species:ncbi:10090">mice</span>
###xml 1020 1024 <span type="species:ncbi:10090">mice</span>
###xml 1163 1167 <span type="species:ncbi:10090">mice</span>
###xml 1326 1330 <span type="species:ncbi:10090">mice</span>
Since it has been reported that immunization of mice with the iNKT cell strong agonist antigen alphaGalCer enhances the T cell response specific for a concomitantly administered antigen, mainly via the NKT cell-mediated licensing of DC function [10], we investigated whether the presence of alphaGalCer on DC could break Tag-specific CTL tolerance in TRAMP mice. As a preliminary experiment, we compared the functional activity of iNKT cells both in TRAMP and WT C57BL/6 male mice by determining the systemic release of IL-4 and IFNgamma after injection of alphaGalCer i.v. As expected, IL-4 and IFNgamma concentration in the serum peaked at 2 and 6 hours after alphaGalCer injection (Fig. 5), with no statistically significant differences between TRAMP and WT C57BL/6 mice. Furthermore, both frequency and absolute number of splenic and hepatic iNKT cells, determined by alphaGalCer-mCD1d tetramer staining, were also comparable between the two strain of mice (data not shown). We then immunized fifteen week-old TRAMP mice with DC pulsed either with Tag-IV and alphaGalCer or with Tag-IV alone. One week later, the presence of Tag-specific CTL in the immunized mice was determined by in vitro restimulation of spleen cells with the TAA. A Tag-specific CTL response, however, could not be found in either group of vaccinated mice (data not shown).
###end p 50
###begin title 51
alphaGal-Cer-mediated release of iNKT-associated cytokines.
###end title 51
###begin p 52
###xml 22 27 <span type="species:ncbi:10090">mouse</span>
alphaGalCer (2 microg/mouse) was administered i.v. to TRAMP (white circles) and WT (black circles) littermates, and blood samples were collected from the tail vein 2, 6 and 24 hours later, and the serum content of IL-4 and IFN-gamma was determined by standard ELISA. Values are reported as concentration of the cytokine (pg/ml) in the sera of each animal (3-4/experimental group) analyzed at the indicated time points. Reported data are representative of at least two independent experiments.
###end p 52
###begin p 53
###xml 241 245 <span type="species:ncbi:10090">mice</span>
Taken together, these data suggest that Tag-specific peripheral CTL tolerance, induced by PC development and progression, is not influenced by iNKT cells, and that iNKT cells exert an as yet undefined role in PC immune surveillance in TRAMP mice.
###end p 53
###begin title 54
Discussion
###end title 54
###begin p 55
###xml 270 274 270 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Swann2">[24]</xref>
###xml 549 553 549 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Tahir1">[15]</xref>
###xml 555 559 555 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Dhodapkar1">[16]</xref>
###xml 561 565 561 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Tachibana1">[17]</xref>
###xml 567 571 567 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Molling1">[18]</xref>
###xml 136 140 <span type="species:ncbi:10090">mice</span>
###xml 371 375 <span type="species:ncbi:10090">mice</span>
###xml 459 464 <span type="species:ncbi:9606">human</span>
###xml 628 632 <span type="species:ncbi:10090">mice</span>
###xml 640 646 <span type="species:ncbi:9606">humans</span>
This study demonstrates that iNKT cells play a relevant role in the immune surveillance of spontaneous prostate adenocarcinoma in TRAMP mice, extending substantially the findings that these cells suppress the onset of spontaneous sarcomas and hematopoietic malignanices [24]. The observation that the lack of iNKT cells correlates with a more aggressive disease in TRAMP mice is consistent with the findings showing that the progression of different types of human cancers, including PC, is accompanied by a significant decrease in iNKT cell number [15], [16], [17], [18]. Thus, iNKT cells appear to play an active role both in mice and in humans in controlling different forms of cancer, ranging from hematological malignancies to sarcoma and carcinoma, arguing for an unconstrained capacity of these cells to survey transformed cells in multiple organs and tissues, through as yet unrecognized mechanisms. Furthermore, our results underscore the relevance of the TRAMP model for deciphering the mechanisms by which the immune system controls solid tumor outgrowth.
###end p 55
###begin p 56
###xml 154 158 154 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Fujii1">[10]</xref>
###xml 160 164 160 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Tonti1">[11]</xref>
###xml 225 226 225 226 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 234 235 234 235 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 348 349 348 349 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 354 355 354 355 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 360 361 360 361 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 366 367 366 367 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 470 474 470 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-DeSanto1">[42]</xref>
###xml 490 491 490 491 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 496 497 496 497 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 610 614 610 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Sica1">[43]</xref>
###xml 778 782 778 782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Renukaradhya1">[44]</xref>
###xml 871 872 871 872 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 877 878 877 878 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 964 968 964 968 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Yanagisawa1">[45]</xref>
###xml 319 336 <span type="species:ncbi:11320">influenza A virus</span>
###xml 390 394 <span type="species:ncbi:10090">mice</span>
###xml 399 405 <span type="species:ncbi:9606">humans</span>
iNKT cells display a powerful helper activity for adaptive T as well as B cell responses, exerted mainly via enhancing antigen presenting functions in DC [10], [11], which result in facilitated priming of peptide-specific CD4+ and CD8+ T cell responses. Furthermore, iNKT cells reduce the immunosuppressive activity of influenza A virus-induced Gr1+CD11b+/CD15+CD11b+ myeloid precursors in mice and humans, respectively, by promoting their maturation into functional DC [42]. Given that Gr1+CD11b+ myeloid precursors share phenotypic and functional characteristics with myeloid-derived suppressor cells (MDSC) [43], iNKT cells might exert their anti-tumor effector functions via modulation of MDSC activity, resulting in a reduced suppression of tumor-specific T cell responses [44]. Such mechanisms could enhance tumor-specific T cell response as well. However, such Gr1+CD11b+ cells appear defective and may actually suppress iNKT cells in tumor-bearing animals [45]
###end p 56
###begin p 57
###xml 294 297 290 293 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 467 468 459 460 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 472 473 464 465 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 478 479 470 471 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 499 503 491 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Sakaguchi1">[46]</xref>
###xml 526 530 518 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-DeglInnocenti1">[29]</xref>
###xml 598 601 586 589 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 97 101 <span type="species:ncbi:10090">mice</span>
###xml 298 302 <span type="species:ncbi:10090">mice</span>
###xml 602 606 <span type="species:ncbi:10090">mice</span>
###xml 748 752 <span type="species:ncbi:10090">mice</span>
###xml 891 895 <span type="species:ncbi:10090">mice</span>
We did not find evidence that supports a correlation between the presence of iNKT cells in TRAMP mice and either the efficiency of the Tag-specific CTL response or a decreased induction of tolerance toward Tag. Indeed, Tag-specific tolerance appeared at similar rates in TRAMP and TRAMPJalpha18-/- mice, and could not be broken by immunization with DC pulsed with Tag-IV plus alphaGalCer. Moreover, we have found that the frequency and function of MDSC as well as CD4+CD25+Foxp3+ regulatory T cells [46] are similar in TRAMP [[29] and Capuano G. et al., manuscript in preparation] and TRAMPJalpha18-/- mice (data not shown), suggesting that a direct cross-talk between iNKT cells and MDSC or regulatory T cells is not a relevant mechanism in TRAMP mice. Altogether, these data provide indirect evidence that iNKT cells are not involved in controlling the induction of CTL tolerance in TRAMP mice and, consequently, the anti-tumor effector T cell response.
###end p 57
###begin p 58
###xml 18 26 18 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 92 93 92 93 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 202 206 202 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Metelitsa1">[47]</xref>
###xml 227 231 227 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Dhodapkar2">[48]</xref>
###xml 306 310 306 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Fiedler1">[49]</xref>
###xml 591 592 587 588 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 621 625 617 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Metelitsa1">[47]</xref>
###xml 627 631 623 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Kawano1">[50]</xref>
###xml 693 700 689 696 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 877 881 873 877 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Song1">[51]</xref>
###xml 987 991 983 987 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Song1">[51]</xref>
###xml 1241 1245 1237 1241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008646-Allavena1">[52]</xref>
###xml 43 48 <span type="species:ncbi:9606">human</span>
###xml 180 185 <span type="species:ncbi:9606">human</span>
###xml 268 273 <span type="species:ncbi:10090">mouse</span>
###xml 349 354 <span type="species:ncbi:10090">mouse</span>
###xml 383 387 <span type="species:ncbi:10090">mice</span>
###xml 593 598 <span type="species:ncbi:10090">mouse</span>
###xml 603 608 <span type="species:ncbi:9606">human</span>
###xml 760 765 <span type="species:ncbi:9606">human</span>
###xml 830 835 <span type="species:ncbi:9606">human</span>
###xml 1025 1030 <span type="species:ncbi:10090">mouse</span>
###xml 1073 1077 <span type="species:ncbi:10090">mice</span>
Studies performed in vitro have shown that human iNKT can be directly cytotoxic against CD1d+ tumor cell targets. The expression of CD1d has been detected on some types of primary human leukemia blasts [47] and on glioma cells [48]. However, the expression of CD1d on mouse tumor cells seems more frequent [49] and our preliminary data suggest that mouse primary PC cells from TRAMP mice express CD1d (data not shown). Nevertheless, it should be taken into consideration that in the absence of strong exogenous ligands such as alphaGalCer, iNKT exhibit little cytotoxic activity against CD1d+ mouse and human tumor cells [47], [50]. Therefore, whether iNKT cells can directly kill tumor cells in vivo remains to be established. Interestingly, in this context, human iNKT cells can kill macrophages that are supposed to infiltrate human neuroblastoma in a CD1d-dependent manner [51], providing a mechanistic link between neuroblastoma infiltration by iNKT cells and an improved prognosis [51]. We can therefore speculate that mouse iNKT cells may control PC growth in TRAMP mice by limiting the number or altering the function of tumor associated macrophages (TAM), which play an important role in supporting neoangiogenesis and tumor growth [52] via IFN-gamma production.
###end p 58
###begin p 59
###xml 60 65 <span type="species:ncbi:10090">mouse</span>
The definition of the mechanism by which iNKT cells control mouse PC growth warrants future investigation.
###end p 59
###begin p 60
We thank M.P. Protti (Istituto Scientifico San Raffaele, Milan, Italy) and M.A. Exley (Beth Israel-Deaconess Medical Center and Harvard Medical School, Boston, MA) for helpful discussions and critical comments on the manuscript.
###end p 60
###begin title 61
Reference
###end title 61
###begin article-title 62
The three Es of cancer immunoediting.
###end article-title 62
###begin article-title 63
Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity.
###end article-title 63
###begin article-title 64
Immune therapy for cancer.
###end article-title 64
###begin article-title 65
The biology of NKT cells.
###end article-title 65
###begin article-title 66
###xml 148 152 <span type="species:ncbi:10090">mice</span>
###xml 157 163 <span type="species:ncbi:9606">humans</span>
An invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specific CD4+ and CD4-8- T cells in mice and humans.
###end article-title 66
###begin article-title 67
An invariant V alpha 24-J alpha Q/V beta 11 T cell receptor is expressed in all individuals by clonally expanded CD4-8- T cells.
###end article-title 67
###begin article-title 68
CD1: antigen presentation and T cell function.
###end article-title 68
###begin article-title 69
Control points in NKT-cell development.
###end article-title 69
###begin article-title 70
Toward an understanding of NKT cell biology: progress and paradoxes.
###end article-title 70
###begin article-title 71
Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein.
###end article-title 71
###begin article-title 72
NKT-cell help to B lymphocytes can occur independently of cognate interaction.
###end article-title 72
###begin article-title 73
Invariant NKT cells amplify the innate immune response to lipopolysaccharide.
###end article-title 73
###begin article-title 74
Harnessing invariant NKT cells in vaccination strategies.
###end article-title 74
###begin article-title 75
NKT cells in immunoregulation of tumor immunity: a new immunoregulatory axis.
###end article-title 75
###begin article-title 76
Loss of IFN-gamma production by invariant NK T cells in advanced cancer.
###end article-title 76
###begin article-title 77
A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma.
###end article-title 77
###begin article-title 78
Increased intratumor Valpha24-positive natural killer T cells: a prognostic factor for primary colorectal carcinomas.
###end article-title 78
###begin article-title 79
###xml 92 100 <span type="species:ncbi:9606">patients</span>
Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma.
###end article-title 79
###begin article-title 80
The regulatory role of Valpha14 NKT cells in innate and acquired immune response.
###end article-title 80
###begin article-title 81
Regulation of antitumour immunity by CD1d-restricted NKT cells.
###end article-title 81
###begin article-title 82
Alpha-galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis.
###end article-title 82
###begin article-title 83
A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas.
###end article-title 83
###begin article-title 84
Differential antitumor immunity mediated by NKT cell subsets in vivo.
###end article-title 84
###begin article-title 85
###xml 36 40 <span type="species:ncbi:10090">mice</span>
Type I NKT cells suppress tumors in mice caused by p53 loss.
###end article-title 85
###begin article-title 86
###xml 32 37 <span type="species:ncbi:10090">mouse</span>
Prostate cancer in a transgenic mouse.
###end article-title 86
###begin article-title 87
###xml 45 49 <span type="species:ncbi:10090">mice</span>
###xml 139 144 <span type="species:ncbi:10090">mouse</span>
###xml 155 160 <span type="species:ncbi:9606">Human</span>
Prostate pathology of genetically engineered mice: definitions and Classification. The consensus report from the Bar Harbor meeting of the mouse models of Human Cancer Consortium Prostate Pathology Commitee.
###end article-title 87
###begin article-title 88
###xml 19 34 <span type="species:ncbi:10633">simian virus 40</span>
###xml 104 109 <span type="species:ncbi:10090">mouse</span>
###xml 119 123 <span type="species:ncbi:10090">mice</span>
Clonal deletion of simian virus 40 large T antigen-specific T cells in the transgenic adenocarcinoma of mouse prostate mice: an important role for clonal deletion in shaping the repertoire of T cells specific for antigens overexpressed in solid tumors.
###end article-title 88
###begin article-title 89
###xml 72 87 <span type="species:ncbi:10633">simian virus 40</span>
###xml 89 93 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 122 126 <span type="species:ncbi:10090">mice</span>
###xml 142 146 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 148 152 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 185 199 <span type="species:ncbi:10245">vaccinia virus</span>
Quantitation of CD8(+) T-lymphocyte responses to multiple epitopes from simian virus 40 (SV40) large T antigen in C57BL/6 mice immunized with SV40, SV40 T-antigen-transformed cells, or vaccinia virus recombinants expressing full-length T antigen or epitope minigenes.
###end article-title 89
###begin article-title 90
Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+CD25+ regulatory T cells.
###end article-title 90
###begin article-title 91
Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization.
###end article-title 91
###begin article-title 92
Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen.
###end article-title 92
###begin article-title 93
Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8+ T lymphocytes.
###end article-title 93
###begin article-title 94
Tumor escape mechanisms in prostate cancer.
###end article-title 94
###begin article-title 95
Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism.
###end article-title 95
###begin article-title 96
###xml 22 26 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
In vitro selection of SV40 T antigen epitope loss variants by site-specific cytotoxic T lymphocyte clones.
###end article-title 96
###begin article-title 97
###xml 98 103 <span type="species:ncbi:10090">mouse</span>
Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model.
###end article-title 97
###begin article-title 98
Critical impact of the kinetics of dendritic cells activation on the in vivo induction of tumor-specific T lymphocytes.
###end article-title 98
###begin article-title 99
Type 2 cytotoxic T lymphocytes modulate the activity of dendritic cells toward type 2 immune responses.
###end article-title 99
###begin article-title 100
Dicer-dependent microRNA pathway controls invariant NKT cell development.
###end article-title 100
###begin article-title 101
Vasculature-Targeted Tumor Necrosis Factor-Alpha Increases the Therapeutic Index of Doxorubicin Against Prostate Cancer.
###end article-title 101
###begin article-title 102
###xml 101 106 <span type="species:ncbi:10090">mouse</span>
Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer.
###end article-title 102
###begin article-title 103
###xml 61 78 <span type="species:ncbi:11320">influenza A virus</span>
###xml 123 127 <span type="species:ncbi:10090">mice</span>
###xml 132 138 <span type="species:ncbi:9606">humans</span>
Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans.
###end article-title 103
###begin article-title 104
Altered macrophage differentiation and immune dysfunction in tumor development.
###end article-title 104
###begin article-title 105
Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma.
###end article-title 105
###begin article-title 106
Hyporesponsiveness to natural killer T-cell ligand alpha-galactosylceramide in cancer-bearing state mediated by CD11b+ Gr-1+ cells producing nitric oxide.
###end article-title 106
###begin article-title 107
Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self.
###end article-title 107
###begin article-title 108
Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells.
###end article-title 108
###begin article-title 109
###xml 50 58 <span type="species:ncbi:9606">patients</span>
Invariant natural killer T cells are preserved in patients with glioma and exhibit antitumor lytic activity following dendritic cell-mediated expansion.
###end article-title 109
###begin article-title 110
###xml 33 39 <span type="species:ncbi:10090">murine</span>
Regulation of CD1d expression by murine tumor cells: escape from immunosurveillance or alternate target molecules?
###end article-title 110
###begin article-title 111
Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells.
###end article-title 111
###begin article-title 112
Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages.
###end article-title 112
###begin article-title 113
The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance.
###end article-title 113
###begin p 114
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 114
###begin p 115
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: Associazione Italiana per la Ricerca sul Cancro:  Ministero del lavoro, della salute e delle politiche sociali:  Fondazione CARIPLO:  Association for International Cancer Research:  The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 115

